Literature DB >> 2514815

Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat.

S Dauvois1, S M Li, C Martel, F Labrie.   

Abstract

Constant release of the androgen 5 alpha-dihydrotestosterone (DHT) in ovariectomized rats bearing DMBA-induced mammary carcinoma caused a marked inhibition of tumor growth induced by 17 beta-estradiol (E2). That DHT acts through interaction with the androgen receptor is supported by the finding that simultaneous treatment with the antiandrogen Flutamide completely prevents DHT action. Particularly illustrative of the potent inhibitory effect of DHT on tumor growth are the decrease by DHT of the number of progressing tumors from 69.2% to 29.2% in E2-treated animals and the increase by DHT of the number of complete responses (disappearance of palpable tumors) from 11.5% to 33.3% in the same groups of animals. The number of new tumors appearing during the 28-day observation period in E2-treated animals decreased from 1.5 +/- 0.3 to 0.7 +/- 0.2 per rat during treatment with DHT, an effect which was also reversed by the antiandrogen Flutamide. The present data demonstrate, for the first time, that androgens are potent inhibitors of DMBA-induced mammary carcinoma growth by an action independent of inhibition of gonadotropin secretion, and suggest an action exerted directly at the tumor level.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2514815     DOI: 10.1007/bf01806301

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  45 in total

1.  Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat.

Authors:  J Asselin; F Labrie
Journal:  J Steroid Biochem       Date:  1978-11       Impact factor: 4.292

2.  Hormonal therapy in cancer of the breast. I. The effect of testosterone propionate therapy on clinical course and hormonal excretion.

Authors:  A SEGALOFF; D GORDON; B N HORWITT; J V SCHLOSSER; P J MURISON
Journal:  Cancer       Date:  1951-03       Impact factor: 6.860

3.  Criteria for evaluating hormones in the 7,12-dimethylbenz[a]-anthracene-induced mammary tumor-rat experimental chemotherapy system.

Authors:  M N Teller; R J Kaufman; C C Stock; M Bowie
Journal:  Cancer Res       Date:  1968-02       Impact factor: 12.701

4.  Androgen action through estrogen receptor in a human breast cancer cell line.

Authors:  D T Zava; W L McGuire
Journal:  Endocrinology       Date:  1978-08       Impact factor: 4.736

5.  Human breast cancer: androgen action mediated by estrogen receptor.

Authors:  D T Zava; W L McGuire
Journal:  Science       Date:  1978-02-17       Impact factor: 47.728

6.  Androstenedione and androst-5-ene-3 beta,17 beta-diol stimulate DMBA-induced rat mammary tumors--role of aromatase.

Authors:  S Dauvois; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

7.  Prolactin receptors and androgen-induced regression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma.

Authors:  M E Costlow; R A Buschow; W L McGuire
Journal:  Cancer Res       Date:  1976-09       Impact factor: 12.701

8.  Androgens on the estrogen receptor. II--Correlation between nuclear translocation and uterine protein synthesis.

Authors:  M Garcia; H Rochefort
Journal:  Steroids       Date:  1977-01       Impact factor: 2.668

9.  THE EFFECTS OF ANDROGENS ON INDUCED MAMMARY TUMOURS IN RATS.

Authors:  S YOUNG; R A BAKER; J E HELFENSTEIN
Journal:  Br J Cancer       Date:  1965-03       Impact factor: 7.640

10.  Rapid induction of mammary carcinoma in the rat and the influence of hormones on the tumors.

Authors:  C HUGGINS; G BRIZIARELLI; H SUTTON
Journal:  J Exp Med       Date:  1959-01-01       Impact factor: 14.307

View more
  8 in total

1.  Androgen resistance in female mice increases susceptibility to DMBA-induced mammary tumors.

Authors:  Ulla Simanainen; Yan Ru Gao; Kirsty A Walters; Geoff Watson; Reena Desai; Mark Jimenez; David J Handelsman
Journal:  Horm Cancer       Date:  2012-06       Impact factor: 3.869

2.  Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.

Authors:  S Li; C Lévesque; C S Geng; X Yan; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

3.  Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate.

Authors:  S Li; M Lepage; Y Mérand; A Bélanger; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

4.  Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide.

Authors:  G Boccuzzi; E Tamagno; E Brignardello; M Di Monaco; M Aragno; O Danni
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

5.  Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the rat.

Authors:  F Labrie; S Li; A Bélanger; J Côté; Y Mérand; M Lepage
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

6.  Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat.

Authors:  S Li; X Yan; A Bélanger; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1994-02       Impact factor: 4.872

7.  Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.

Authors:  F Labrie; S Li; C Labrie; C Lévesque; Y Mérand
Journal:  Breast Cancer Res Treat       Date:  1995-03       Impact factor: 4.872

Review 8.  The role of androgens in experimental rodent mammary carcinogenesis.

Authors:  Jaesung Choi; Basil Psarommatis; Yan Ru Gao; Yu Zheng; David J Handelsman; Ulla Simanainen
Journal:  Breast Cancer Res       Date:  2014-11-25       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.